See more : Shop Apotheke Europe N.V. (SAE.DE) Income Statement Analysis – Financial Results
Complete financial analysis of Zogenix, Inc. (ZGNX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Zogenix, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Dynasty Gold Corp. (DGDCF) Income Statement Analysis – Financial Results
- Doosan Fuel Cell Co., Ltd. (336260.KS) Income Statement Analysis – Financial Results
- Synlait Milk Limited (SML.NZ) Income Statement Analysis – Financial Results
- Guangzhou Restaurant Group Company Limited (603043.SS) Income Statement Analysis – Financial Results
- Granules India Limited (GRANULES.NS) Income Statement Analysis – Financial Results
Zogenix, Inc. (ZGNX)
About Zogenix, Inc.
Zogenix, Inc., a biopharmaceutical company, develops and commercializes therapies to transform the lives of patients and their families living with rare diseases in the United States. The company's lead product candidate is the Fintepla, a low-dose fenfluramine, which is in Phase III clinical trials for the treatment of seizures associated with Dravet syndrome, as well as to treat seizures associated with Lennox-Gastaut syndrome; and that is in Phase II clinical trials for the treatment of other rare epileptic syndromes and diseases. It is also developing MT1621, an investigational therapy for the treatment of a rare genetic disorder called thymidine kinase 2 deficiency. Zogenix, Inc. has a collaboration with Tevard Biosciences for the research, development and commercialization of novel gene therapies for Dravet Syndrome and other genetic epilepsies. The company was formerly known as SJ2 Therapeutics, Inc. and changed its name to Zogenix, Inc. in August 2006. Zogenix, Inc. was incorporated in 2006 and is headquartered in Emeryville, California.
| Metric | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 81.69M | 13.64M | 3.65M | 0.00 | 9.82M | 28.85M | 27.18M | 40.53M | 33.01M | 44.33M | 37.58M | 23.44M | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 4.83M | 542.00K | 0.00 | 0.00 | 10.73M | 22.47M | 22.70M | 31.88M | 22.48M | 20.85M | 20.50M | 13.69M | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 76.86M | 13.10M | 3.65M | 0.00 | -908.00K | 6.38M | 4.48M | 8.65M | 10.53M | 23.48M | 17.08M | 9.75M | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 94.08% | 96.03% | 100.00% | 0.00% | -9.25% | 22.12% | 16.49% | 21.35% | 31.89% | 52.96% | 45.45% | 41.60% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 142.66M | 138.00M | 115.64M | 100.93M | 67.45M | 41.84M | 27.86M | 18.94M | 12.81M | 21.41M | 33.04M | 28.64M | 21.44M | 33.91M | 24.33M | 4.90M |
| General & Administrative | 0.00 | 99.57M | 33.63M | 23.22M | 21.12M | 20.99M | 22.41M | 88.90M | 50.04M | 49.49M | 60.46M | 51.27M | 14.10M | 11.82M | 4.73M | 1.47M |
| Selling & Marketing | 0.00 | 0.00 | 27.17M | 15.73M | 4.76M | 6.00M | 3.94M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 148.52M | 99.57M | 60.79M | 38.95M | 25.89M | 27.00M | 26.35M | 88.90M | 50.04M | 49.49M | 60.46M | 51.27M | 14.10M | 11.82M | 4.73M | 1.47M |
| Other Expenses | 7.89M | 3.94M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -10.00K | 10.00K |
| Operating Expenses | 299.07M | 241.52M | 176.43M | 139.88M | 93.33M | 68.84M | 54.21M | 107.84M | 62.85M | 70.91M | 93.50M | 79.91M | 35.54M | 45.73M | 29.05M | 6.38M |
| Cost & Expenses | 303.90M | 242.06M | 176.43M | 139.88M | 104.06M | 91.30M | 76.91M | 139.71M | 85.33M | 91.76M | 114.00M | 93.60M | 35.54M | 45.73M | 29.05M | 6.38M |
| Interest Income | 659.00K | 2.89M | 9.80M | 7.17M | 1.09M | 443.00K | 0.00 | 20.00K | 18.00K | 53.00K | 37.00K | 5.00K | 10.00K | 696.00K | 0.00 | 0.00 |
| Interest Expense | 15.28M | 3.76M | 2.00K | 6.00K | 2.64M | 2.83M | 0.00 | 3.09M | 6.61M | 10.31M | 7.64M | 10.01M | 9.19M | 1.72M | 1.35M | 980.00K |
| Depreciation & Amortization | 9.46M | 5.47M | 1.27M | 155.00K | 425.00K | 1.40M | 1.62M | 1.63M | 1.81M | 1.60M | 1.58M | 1.43M | 5.31M | 1.10M | 410.00K | 1.96M |
| EBITDA | -202.58M | -217.58M | -418.23M | -123.75M | -123.75M | -66.43M | 11.86M | 13.39M | -72.44M | -35.47M | -74.68M | -62.11M | -31.39M | -42.75M | -25.92M | -4.42M |
| EBITDA Ratio | -247.98% | -1,594.84% | -11,464.72% | 0.00% | -1,260.03% | -230.25% | 43.65% | 33.03% | -219.44% | -80.02% | -198.75% | -264.96% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -212.03M | -247.72M | -429.82M | -141.18M | -119.94M | -72.69M | -47.73M | -20.04M | -53.19M | -47.43M | -76.42M | -70.16M | -35.54M | -45.73M | -29.05M | -6.38M |
| Operating Income Ratio | -259.56% | -1,815.71% | -11,782.37% | 0.00% | -1,221.22% | -251.94% | -175.58% | -49.44% | -161.13% | -107.00% | -203.39% | -299.29% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -15.28M | 20.91M | 10.32M | 17.46M | -6.09M | 3.05M | -9.88M | 28.71M | -27.66M | 50.00K | -7.49M | -3.39M | -1.17M | 1.18M | 1.37M | 980.00K |
| Income Before Tax | -227.31M | -226.81M | -419.50M | -123.72M | -126.02M | -69.63M | -57.61M | 8.67M | -80.86M | -47.38M | -83.91M | -73.55M | -36.71M | -44.55M | -27.68M | -5.40M |
| Income Before Tax Ratio | -278.26% | -1,662.45% | -11,499.53% | 0.00% | -1,283.19% | -241.37% | -211.92% | 21.39% | -244.93% | -106.89% | -223.31% | -313.77% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 105.00K | -17.43M | 10.32M | 17.47M | -3.44M | -948.00K | -15.90M | 84.00K | -21.05M | 5.00K | -9.00K | 10.00K | 8.02M | 2.90M | 2.72M | 0.00 |
| Net Income | -227.41M | -209.38M | -419.50M | -123.91M | -126.82M | -69.71M | 26.14M | 8.59M | -80.86M | -47.39M | -83.90M | -73.56M | -45.89M | -45.57M | -27.68M | -5.40M |
| Net Income Ratio | -278.39% | -1,534.73% | -11,499.53% | 0.00% | -1,291.28% | -241.62% | 96.18% | 21.19% | -244.93% | -106.90% | -223.29% | -313.81% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -4.24 | -3.90 | -9.74 | -3.27 | -4.65 | -2.81 | 1.22 | 0.48 | -5.96 | -4.71 | -15.72 | -141.03 | -36.50 | -272.06 | -395.43 | -108.00 |
| EPS Diluted | -4.24 | -3.90 | -9.74 | -3.27 | -4.65 | -2.81 | 1.22 | 0.47 | -5.96 | -4.71 | -15.72 | -141.03 | -36.50 | -272.06 | -395.43 | -108.00 |
| Weighted Avg Shares Out | 53.69M | 53.69M | 43.07M | 37.89M | 27.30M | 24.79M | 21.45M | 17.83M | 13.57M | 10.07M | 5.34M | 521.63K | 1.26M | 167.50K | 70.00K | 50.00K |
| Weighted Avg Shares Out (Dil) | 53.69M | 53.69M | 43.07M | 37.89M | 27.30M | 24.79M | 21.45M | 18.13M | 13.57M | 10.07M | 5.34M | 521.63K | 1.26M | 167.50K | 70.00K | 50.00K |
Needle-Free Drug Injection Systems Business Analysis Report 2023-2030 Featuring AKRA Dermojet, Crossject, D`Antonio Consultants, PharmaJet, and Zogenix
Dublin, Aug. 01, 2024 (GLOBE NEWSWIRE) -- The "Needle-Free Drug Injection Systems - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering. The global market for Needle-Free Drug Injection Systems is estimated at US$15.9 Billion in 2023 and...
Zogenix To Present New Long-term Data on FINTEPLA® (fenfluramine) in Lennox-Gastaut Syndrome (LGS) at AAN 2022
EMERYVILLE, Calif., March 04, 2022 (GLOBE NEWSWIRE) -- Zogenix (Nasdaq: ZGNX), a global biopharmaceutical company developing and commercializing rare disease therapies, announced that new data from the company's research and development program for FINTEPLA® (fenfluramine) in Lennox Gastaut syndrome (LGS) will...
Zogenix (ZGNX) Reports Q4 Loss, Tops Revenue Estimates
Zogenix (ZGNX) delivered earnings and revenue surprises of -8.89% and 1.46%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Why Zogenix Flew Higher Before Leveling Off This Week
The company attracts a determined suitor from abroad.
Top Biotech Stocks To Buy Now? 5 For Your Late January Watchlist
Which biotech stocks are you watching today?
Zogenix (ZGNX) Stock Surges on Acquisition Offer From UCB
Belgium-based UCB is set to acquire Zogenix (ZGNX) for a total transaction value of $1.9 billion in cash. The transaction is likely to be completed by second-quarter 2022.
Zogenix (ZGNX) Stock Jumps 65.7%: Will It Continue to Soar?
Zogenix (ZGNX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
ZGNX Stock: The $1.9B UCB Deal That Has Zogenix Shares Zooming Higher Today
Zogenix (ZGNX) stock is skyrocketing on Wednesday following news that UCB (UCBJY) intends to acquire the company in a $1.9 billion deal. The post ZGNX Stock: The $1.9B UCB Deal That Has Zogenix Shares Zooming Higher Today appeared first on...
Why Zogenix Stock Is on Fire Today
A buyout deal is lighting a fire underneath the biotech's shares today.
Why Zogenix Shares Are Soaring Today
Zogenix Inc (NASDAQ: ZGNX) is trading significantly higher Wednesday morning after the company announced it received a proposal to be acquired by UCB for approximately $1.9 billion. Under terms of the agreement, UCB will offer to purchase all outstanding shares of Zogenix for...
Source: https://incomestatements.info
Category: Stock Reports
What were Zogenix’s revenue and net loss in 2021?
Net loss for the second quarter ended June 30, 2021, was $58.9 million, or a net loss of $1.05 per share compared with a net loss of $53.3 million, or a net loss of $0.96 per share, in the second quarter ended June 30, 2020. The Company recorded $32.5 million in revenue for the six months ended June 30, 2021.